Background

Pulmonary arterial hypertension (PAH) remains one of the most lethal complications of mixed connective tissue disease (MCTD), with estimated prevalence of 10–45% depending on screening methodology. Current detection relies on echocardiographic estimation of pulmonary artery systolic pressure followed by right heart catheterization (RHC), but this approach identifies PAH only after established hemodynamic derangement, missing the critical window for early vasodilator intervention when vascular remodeling may still be partially reversible.

Angiopoietin-2 (Ang-2) is released from endothelial Weibel-Palade bodies during vascular stress and destabilizes vessel integrity by competitively antagonizing the stabilizing Tie2 receptor signal from Angiopoietin-1 (Ang-1). Elevated Ang-2/Ang-1 ratios have been reported in idiopathic PAH and systemic sclerosis-associated PAH, but longitudinal trajectory analysis in MCTD — where anti-U1 RNP-driven endothelial injury is the primary pathogenic driver — has not been systematically performed.

Hypothesis

Serial measurement of serum Ang-2/Ang-1 ratio at 3-month intervals in anti-U1 RNP-positive MCTD patients will reveal a characteristic sigmoid acceleration pattern 12–24 months before RHC-confirmed PAH (mean pulmonary artery pressure ≥20 mmHg at rest). Specifically, a sustained Ang-2/Ang-1 ratio >3.5 or a rate of change exceeding 0.4 units per quarter over two consecutive measurements will predict incident PAH with >80% sensitivity and >75% specificity, outperforming echocardiographic screening alone.

Testable Predictions

1. In a prospective cohort of ≥150 anti-U1 RNP-positive MCTD patients without baseline PAH, serial Ang-2/Ang-1 ratios will demonstrate non-linear (sigmoid) trajectory in PAH progressors versus stable linear trajectory in non-progressors, detectable by mixed-effects models with spline terms (likelihood ratio test p<0.01).
2. Time-dependent ROC analysis at the 12-month prediction horizon will show AUC >0.82 for Ang-2/Ang-1 trajectory slope versus AUC <0.70 for single-timepoint echocardiographic RVSP.
3. Addition of serum endothelin-1 and NT-proBNP to the Ang-2/Ang-1 kinetic model will improve net reclassification index by >0.15 compared to the angiopoietin ratio alone.
4. Endothelial progenitor cell (EPC) counts will inversely correlate with Ang-2/Ang-1 ratio acceleration (Spearman ρ < −0.45), suggesting failed vascular repair as a mechanistic link.

Limitations

• MCTD is relatively rare; multi-center recruitment would be necessary to achieve adequate sample size and statistical power within a feasible timeframe.
• Ang-2 levels can be influenced by intercurrent infections, surgery, and other vascular insults, requiring careful adjudication of confounders and protocol-specified exclusion windows.
• The proposed sigmoid kinetic model assumes a common trajectory shape; individual heterogeneity may require latent class mixed models, increasing complexity.
• RHC as the gold standard carries procedural risk and may introduce verification bias if clinicians selectively catheterize patients with elevated biomarkers.
• Anti-U1 RNP positivity encompasses a heterogeneous population; not all will have MCTD by Alarcon-Segovia or Kasukawa criteria, requiring rigorous phenotypic classification.

Clinical Significance

Early identification of PAH in MCTD during the pre-hemodynamic phase — when endothelial dysfunction is present but irreversible vascular remodeling has not yet occurred — could enable prophylactic vasodilator therapy (e.g., ambrisentan, macitentan) and intensive monitoring that may alter the natural history of this devastating complication. A simple serum biomarker ratio measured quarterly is far more scalable than serial echocardiography and could be integrated into routine rheumatology follow-up panels for high-risk MCTD patients worldwide.

LES AI • DeSci Rheumatology